#Indian Pharma

Articles tagged with "Indian Pharma"

3 articles found

Natco Pharma: A Long-Term Investor's Honest Assessment at ₹883

A deep-dive analysis of Natco Pharma using all 12 pharma-specific metrics — revenue mix, FDA compliance, Para IV pipeline, return ratios, and valuation — at a time when the stock sits 28% off its 52-week high.

The FDA's Naughty List: What Indian Pharma Investors Need to Know

Warning letters, import alerts, and consent decrees — a complete guide to US FDA enforcement actions against Indian pharma companies, with case studies on Ranbaxy, Sun Pharma, Cipla, Lupin and more.

Dr. Reddy's Q4 FY26 Results: A Long-Term Investor's Honest Take

A long-term Dr. Reddy's investor breaks down Q4 FY26 earnings, what looks promising for FY27, and the concerns worth watching closely.

Ambika Iyer

May 12, 2026

10 min read